Donidalorsen (Dawnzera) for Prevention of Hereditary Angioedema Attacks
Abstract
Donidalorsen (Dawnzera – Ionis), a subcutaneously injected prekallikrein-directed antisense oligonucleotide, has been approved by the FDA for prevention of hereditary angioedema (HAE) attacks in patients ≥12 years old. It is the first RNA-targeted drug to be approved in the US for this indication.
Fields of Study & Subjects
Coagulation
Bradykinin
Polyphosphates
and Angioedema
Hemophilia Treatment and Research
Vascular Anomalies and Treatments
Publication details
- Journal / source
- The medical letter on drugs and therapeutics/The medical letter
- Volume
- 68
- Issue
- 1746
- Pages
- 12–14
- Publication date
- 19 January 2026
- Language
- EN